Practice

Study: Pharmacists Should Learn Nuances of Biosimilars

April 7th 2020

By Gianna Melillo

There are multiple distinctions in labeling indications between biosimilars and brand products, and pharmacists must become familiar with these to be of maximum service to patients and physicians, according to a review.

NCCN Guidelines May Aid US Biosimilar Uptake

April 7th 2020

By Skylar Jeremias

Article

The National Comprehensive Cancer Network (NCCN) Guidelines may help get biosimilars into circulation because the NCCN will recommend them for off-label uses.

Report: Biosimilars Are Underutilized in IBD

April 7th 2020

By Deana Ferreri, PhD

Article

In inflammatory bowel diseases (IBD), biosimilars have been available for roughly 5 years, but more evidence may be necessary to persuade medical community to increase usage, according to a study.

Critics Assail Nonmedical Switching Policy in Canadian Provinces

March 31st 2020

By Tony Hagen

Article

Canadian provinces encounter opposition in their move to implement forced switching of patients from reference products to biosimilars.

Study: Office-Based Providers Latch Onto Biosimilars

March 26th 2020

By Tony Hagen

Article

When providers get used to biosimilars, they tend to prescribe them exclusively, according to a study in The American Journal of Managed Care.

Investigators Recommend a More Systematic Effort to Get Biosimilars Adopted

March 25th 2020

By Deana Ferreri, PhD

Article

A gentle, persuasive effort to get patients and physicians to adopt biosimilars is likely to work better than a heavy-handed approach, say Canadian investigators, who recommend more study of how mindsets and prescribing practices are changed.

Patel: Biosimilar Education Can Be Challenging

March 21st 2020

By The Center for Biosimilars Staff

Article

Kashyap B. Patel, MD, has worn many hats in the struggle to broaden biosimilar access. He is an independent oncology practitioner, a member of the Community Oncology Alliance (COA), and a representative of International Oncology Network (ION) Solutions, a large drug purchasing organization. Bringing biosimilars to a broader population of patients has involved negotiations with payers, persistence on Capitol Hill, and education, he explains in an interview.

Editorial Calls for Monitoring of Low-Dose Methotrexate Users for Adverse Events in Light of New RCT Data

February 26th 2020

By Deana Ferreri, PhD

Article

The use of low-dose methotrexate in rheumatoid arthritis dates back more than 30 years, but despite these decades of clinical use, data on adverse effects have come mostly from observational studies rather than randomized controlled trials (RCTs), the authors say.

2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says

February 21st 2020

By Deana Ferreri, PhD

Article

A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

What Are the Factors for Starting Anti-TNF Inhibitor Biosimilars in RA and AS?

February 11th 2020

By Deana Ferreri, PhD

Article

The study aimed to provide insight into the real-world patterns of biosimilar initiation in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Korea by identifying patient characteristics and other factors associated with starting biosimilars using a logistic regression model.